A novel intranasal administration adenoviral vector-based platform for rapid COVID-19 vaccine development

The coronavirus SARS-CoV-2 has a severe impact on global public health, and the emerging variants threaten the efficacy of the circulating vaccines. Here, we report that a single vaccination with a non-replicated Chimpanzee adenovirus-based vaccine against the SARS-CoV-2 B.1.617.2 variant (JS1-delta) elicits potent humoral, cellular and mucosal immunity in mice. Additionally, a single intranasal administration of JS1-delta provides sufficient protection against B.1.617.2 challenge in mice. This study indicates that Chimpanzee adenovirus type 3 (ChAd3) derived vector represents a promising platform for antiviral vaccine development against respiratory infections, and that JS1-delta is worth further investigation in human clinical trials. ### Competing Interest Statement The authors have declared no competing interest.